A single dose study of mexiletine (Ko 1173)

James Cereghino, B. J. Wilder, H. J. Kupferberg, W. D. Yonekawa, R. J. Perchalski, R. E. Ramsey, B. G. White, J. K. Penry, L. D. Smith

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Serum concentrations of mexiletine after a single dose were determined in 8 adult Caucasian males with complex partial seizures who were continuing to receive other antiepileptic drugs. Two patients each received a single dose of either 100, 200, 300, or 400 mg mexiletine. Serum concentrations were determined by two gas chromatographic methods. Serum concentrations ranged up to 795 ng/ml. Peak concentrations occurred 1 to 3 hr after administration of the drug and were significantly different between the 100 and 300 mg, 100 and 400 mg, 200 and 300 mg, and 200 and 400 mg doses. Differences between the other doses were not significant. Serum concentrations declined monoexponentially. Half life ranged from 2.7 to 7.2 hr. Numerous papers have appeared in the European literature on the use of mexiletine to treat cardiac arrhythmias. Preliminary studies in the United States suggest the use of mexiletine as an adjunct for therapy of epilepsy.

Original languageEnglish (US)
Pages (from-to)665-672
Number of pages8
JournalEpilepsia
Volume16
Issue number5
StatePublished - 1975
Externally publishedYes

Fingerprint

Mexiletine
Serum
Anticonvulsants
Half-Life
Cardiac Arrhythmias
Epilepsy
Seizures
Gases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cereghino, J., Wilder, B. J., Kupferberg, H. J., Yonekawa, W. D., Perchalski, R. J., Ramsey, R. E., ... Smith, L. D. (1975). A single dose study of mexiletine (Ko 1173). Epilepsia, 16(5), 665-672.

A single dose study of mexiletine (Ko 1173). / Cereghino, James; Wilder, B. J.; Kupferberg, H. J.; Yonekawa, W. D.; Perchalski, R. J.; Ramsey, R. E.; White, B. G.; Penry, J. K.; Smith, L. D.

In: Epilepsia, Vol. 16, No. 5, 1975, p. 665-672.

Research output: Contribution to journalArticle

Cereghino, J, Wilder, BJ, Kupferberg, HJ, Yonekawa, WD, Perchalski, RJ, Ramsey, RE, White, BG, Penry, JK & Smith, LD 1975, 'A single dose study of mexiletine (Ko 1173)', Epilepsia, vol. 16, no. 5, pp. 665-672.
Cereghino J, Wilder BJ, Kupferberg HJ, Yonekawa WD, Perchalski RJ, Ramsey RE et al. A single dose study of mexiletine (Ko 1173). Epilepsia. 1975;16(5):665-672.
Cereghino, James ; Wilder, B. J. ; Kupferberg, H. J. ; Yonekawa, W. D. ; Perchalski, R. J. ; Ramsey, R. E. ; White, B. G. ; Penry, J. K. ; Smith, L. D. / A single dose study of mexiletine (Ko 1173). In: Epilepsia. 1975 ; Vol. 16, No. 5. pp. 665-672.
@article{182f58b0bb354dd48135dae51554281c,
title = "A single dose study of mexiletine (Ko 1173)",
abstract = "Serum concentrations of mexiletine after a single dose were determined in 8 adult Caucasian males with complex partial seizures who were continuing to receive other antiepileptic drugs. Two patients each received a single dose of either 100, 200, 300, or 400 mg mexiletine. Serum concentrations were determined by two gas chromatographic methods. Serum concentrations ranged up to 795 ng/ml. Peak concentrations occurred 1 to 3 hr after administration of the drug and were significantly different between the 100 and 300 mg, 100 and 400 mg, 200 and 300 mg, and 200 and 400 mg doses. Differences between the other doses were not significant. Serum concentrations declined monoexponentially. Half life ranged from 2.7 to 7.2 hr. Numerous papers have appeared in the European literature on the use of mexiletine to treat cardiac arrhythmias. Preliminary studies in the United States suggest the use of mexiletine as an adjunct for therapy of epilepsy.",
author = "James Cereghino and Wilder, {B. J.} and Kupferberg, {H. J.} and Yonekawa, {W. D.} and Perchalski, {R. J.} and Ramsey, {R. E.} and White, {B. G.} and Penry, {J. K.} and Smith, {L. D.}",
year = "1975",
language = "English (US)",
volume = "16",
pages = "665--672",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A single dose study of mexiletine (Ko 1173)

AU - Cereghino, James

AU - Wilder, B. J.

AU - Kupferberg, H. J.

AU - Yonekawa, W. D.

AU - Perchalski, R. J.

AU - Ramsey, R. E.

AU - White, B. G.

AU - Penry, J. K.

AU - Smith, L. D.

PY - 1975

Y1 - 1975

N2 - Serum concentrations of mexiletine after a single dose were determined in 8 adult Caucasian males with complex partial seizures who were continuing to receive other antiepileptic drugs. Two patients each received a single dose of either 100, 200, 300, or 400 mg mexiletine. Serum concentrations were determined by two gas chromatographic methods. Serum concentrations ranged up to 795 ng/ml. Peak concentrations occurred 1 to 3 hr after administration of the drug and were significantly different between the 100 and 300 mg, 100 and 400 mg, 200 and 300 mg, and 200 and 400 mg doses. Differences between the other doses were not significant. Serum concentrations declined monoexponentially. Half life ranged from 2.7 to 7.2 hr. Numerous papers have appeared in the European literature on the use of mexiletine to treat cardiac arrhythmias. Preliminary studies in the United States suggest the use of mexiletine as an adjunct for therapy of epilepsy.

AB - Serum concentrations of mexiletine after a single dose were determined in 8 adult Caucasian males with complex partial seizures who were continuing to receive other antiepileptic drugs. Two patients each received a single dose of either 100, 200, 300, or 400 mg mexiletine. Serum concentrations were determined by two gas chromatographic methods. Serum concentrations ranged up to 795 ng/ml. Peak concentrations occurred 1 to 3 hr after administration of the drug and were significantly different between the 100 and 300 mg, 100 and 400 mg, 200 and 300 mg, and 200 and 400 mg doses. Differences between the other doses were not significant. Serum concentrations declined monoexponentially. Half life ranged from 2.7 to 7.2 hr. Numerous papers have appeared in the European literature on the use of mexiletine to treat cardiac arrhythmias. Preliminary studies in the United States suggest the use of mexiletine as an adjunct for therapy of epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0016780852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016780852&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 665

EP - 672

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 5

ER -